A randomised controlled trial evaluating the effects of hormone replacement therapy (HRT) on bone mineral density (BMD) and disease course in postmenopausal women with rheumatoid arthritis (RA)
| ISRCTN | ISRCTN46523456 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN46523456 |
| Protocol serial number | N/A |
| Sponsor | Sahlgrenska Academy at Göteborg University (Sweden) |
| Funders | Regional Research Sources from Västra Götaland (Sweden), Novo Nordisk Scandinavia AB Research Foundation (Sweden), The Rune and Ulla Amlövs Foundation for Neurological and Rheumatological Research (Rune och Ulla Amlövs Stiftelse for Neurologisk och Reumatologisk Forskning) (Sweden), The Research Foundation of Trygg-Hansa (Sweden), The Swedish and Göteborg Association against Rheumatism (Sweden), Reumaforskningsfond Margareta (Sweden), King Gustav V's 80-years Foundation (Sweden), The Medical Society of Göteborg (Sweden), The Medical Faculty of Göteborg (LUA) (Sweden), Nycomed (Sweden) - provided the calcium and vitamin D3 medication |
- Submission date
- 03/03/2004
- Registration date
- 22/04/2004
- Last edited
- 30/06/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Hans Carlsten
Scientific
Scientific
Sahlgrenska Academy at Göteborg University
The Department of Rheumatology and Inflammation Research
Guldhedsgatan 10
Göteborg
S-413 46
Sweden
| hans.carlsten@rheuma.gu.se |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | Rheumatoid arthritis (RA) is a chronic disabling inflammatory rheumatic disease involving predominantly the joints and often also other organs such as the lungs and heart. The disease increases the risk of developing osteoporosis and fractures related to the reduced bone mineral density (BMD). The prevalence of the disease is 0.5 - 1% and women are more frequently affected. The aims of the study were to assess the effects of HRT on: 1. The clinical disease activity 2. Laboratory measures of inflammation 3. BMD 4. Joint destruction by scoring radiographs 5. Biochemical markers of bone and cartilage metabolism 6. Pro-inflammatory cytokines and insulin like growth factor 1 |
| Ethics approval(s) | Ethics approval received from the Ethics Committee at the Göteborg University. |
| Health condition(s) or problem(s) studied | Rheumatoid arthritis |
| Intervention | Eighty-eight women were randomised to: 1. HRT group (41 women): receive HRT and 500 mg calcium and 400 IU vitamin D3 2. Control group (47 women): receive 500 mg calcium and 400 IU vitamin D3 alone |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Hormone replacement therapy |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 31/12/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target sample size at registration | 88 |
| Key inclusion criteria | 1. Postmenopausal women with RA between 45 and 55 years old 2. Active disease, which met at least two of the following criteria: 2.1. At least six painful joints 2.2. At least three swollen joints 2.3. Erythrocyte sedimentation rate (ESR) at least 20 mm per hour 2.4. C-reactive protein (CRP) at least 10 mg/l 2.5. Fulfils the American Rheumatism Association 1987 revised criteria for adult RA 3. A maximum daily dose of 7.5 mg of prednisolone was accepted 4. Not receiving, or had not been using in the past two years, drugs affecting bone metabolism (HRT or bisphosphonates), except calcium and vitamin D3, which were allowed 5. No contra-indications to HRT |
| Key exclusion criteria | Does not comply with above inclusion criteria. |
| Date of first enrolment | 01/04/2004 |
| Date of final enrolment | 31/12/2005 |
Locations
Countries of recruitment
- Sweden
Study participating centre
Sahlgrenska Academy at Göteborg University
Göteborg
S-413 46
Sweden
S-413 46
Sweden
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/04/2004 | Yes | No | |
| Results article | results | 01/07/2009 | Yes | No |